Search company, investor...

Stage

Acquired | Acquired

Total Raised

$2M

About Convoy Therapeutics

Convoy Therapeutics is a biotechnology company focused on enhancing delivery of pharmaceuticals and macromolecules into the dermal layer of the skin for the treatment of psoriasis, atopic dermatitis, and malignant melanoma. Convoy's platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development.

Headquarters Location

4262 Blue Diamond Road Suite 102-270

Las Vegas, Nevada, 89139,

United States

702-448-1826

Loading...

Loading...

Convoy Therapeutics Patents

Convoy Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2013

Membrane biology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation

Application

Application Date

2/11/2013

Grant Date

Title

Related Topics

Membrane biology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation

Status

Application

Latest Convoy Therapeutics News

CTX Acquires Promising Proprietary Drug Delivery Assets

Aug 4, 2015

TA Instruments acquires assets of Bose Electroforce Group Built on peptide-based skin -penetration platform technology developed in the laboratory of Samir Mitragotri, PhD, at the University of California Santa Barbara, the Convoy Therapeutics assets include proprietary formulations for both therapeutic and aesthetic applications. The proprietary peptide platform technology is uniquely capable of transporting small and large molecules, with a wide range of molecular weights, including biologics , into the skin and ensuring that they remain at the site of local placement. The technology represents a new approach for improved topical delivery of a wide range of active ingredients. Of the proprietary formulations acquired, Khalay HATM, a formulation of hyaluronic acid, has shown superior moisturizing and wrinkle-reduction performance for aesthetic applications. CyclopsorbTM is a promising disease-modifying therapeutic that targets mild-to-moderate psoriasis. Both formulations utilize the CTX peptide-based skin-penetration platform technology. CTX will commercialize the existing proprietary formulations through focused partnerships, continue to work on new applications and out-license the platform technology for the therapeutic and aesthetic markets. View source version on businesswire.com: http://www.businesswire.com/news/home/20150804006520/en/ CTX Technology Inc.

Convoy Therapeutics Frequently Asked Questions (FAQ)

  • Where is Convoy Therapeutics's headquarters?

    Convoy Therapeutics's headquarters is located at 4262 Blue Diamond Road, Las Vegas.

  • What is Convoy Therapeutics's latest funding round?

    Convoy Therapeutics's latest funding round is Acquired.

  • How much did Convoy Therapeutics raise?

    Convoy Therapeutics raised a total of $2M.

  • Who are the investors of Convoy Therapeutics?

    Investors of Convoy Therapeutics include CTX Virtual Technologies.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.